Overview

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue. The MGMT gene promoter is a section of deoxyribonucleic acid (DNA) that acts as a controlling element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be a predictive marker for benefit from temozolomide (TMZ) treatment.

Phase:

Phase 3

Details

Lead Sponsor:

EMD Serono

Collaborators:

European Organisation for Research and Treatment of Cancer - EORTC
Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Dacarbazine
Temozolomide